Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192465 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00192465 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 30 participants.
The verdict
NCT00192465, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
To provide safety, tolerability, pharmacokinetic, and immunogenicity data for MEDI-524 administered initially as a single dose to healthy adults in a dose escalation safety study before testing in the targeted pediatric population.
Interventions
- BIOLOGICAL MEDI-524 (Numax-TM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-11 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192465
The ClinicalTrials.gov registry entry for NCT00192465 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-524 (Numax-TM) is the first listed.
NCT00192465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192465 about?
NCT00192465 is a clinical study titled "Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults". To provide safety, tolerability, pharmacokinetic, and immunogenicity data for MEDI-524 administered initially as a single dose to healthy adults in a dose escalation safety study before testing in the targeted pediatric population.
What is the current status of trial NCT00192465?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-11. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00192465?
The interventions under investigation include: MEDI-524 (Numax-TM) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192465?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.